In our study, immunohistochemical staining of PD‐L1 and LAG‐3 did not correlate well with the expression levels of CD274 and LAG3 genes, respectively, and did not help classify clusters A, B, and C. Therefore, we suggest trying a treatment strategy using a combination of anti‐PD‐1 and anti‐LAG‐3 blockade for all DLBCL patients requiring immunotherapy, rather than using them individually for the patients in each TIME cluster. This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.